New immune therapy tested for stubborn lymphoma
NCT ID NCT06510361
Summary
This study is testing whether the drug epcoritamab can help people with follicular lymphoma whose cancer did not completely disappear after their initial treatment. The drug works by activating the immune system to attack cancer cells. About 35 adults who had a partial response or stable disease after first-line therapy will receive this experimental treatment for up to 12 cycles and be followed for 2 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
-
Stanford
RECRUITINGStanford, California, 94305, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.